Research

 

Companies Racing to Use CRISPR to Fight Disease

While a researcher at the Harvard School of Public Health, Ashley performed genetic engineering projects using the CRISPR Cas-9 system. She continues using this gene-editing tool in her current research in Cambridge biotech, CRISPR Tx.  

Posters & Publications:

Melanie Allen. "Allogeneic CAR-T Cells with Multiple Therapeutically Favorable Edits Can Be Created Efficiently Using CRISPR/Cas9."American Society of Gene & Cell Therapy Annual Meeting. Cell Therapies Poster Session. 16-19 May. 2018. Chicago, IL, USA. 

Zinkal Padalia*, Ashley Porras*. "Allogeneic CRISPR engineered anti-CD70 CAR-T cells demonstrate potent preclinical activity against both solid and hematological cancer cells." American Association of Cancer Research Annual Meeting. Immunology Poster Session. 14-18 April. 2018. Chicago, IL, USA. 

Henia Dar*, Daniel Henderson*. "Allogeneic Chimeric Antigen Receptor T-Cells Targeting B-cell Maturation Antigen." American Association of Cancer Research Annual Meeting. Clinical Research (Excluding Clinical Trials) Poster Session. 14-18 April. 2018. Chicago, IL, USA. 

Zinkal Padalia*, Ashley Porras*. "Production of site-specific Allogeneic CD19 CAR-T Cells by CRISPR-Cas9 for B-Cell Malignancies." Society for Immunotherapy of Cancer Conference. Cellular Therapies Poster Session. 9-12 Nov. 2017. National Harbor, MD, USA. 

Huajin Wang. "Seipin Is Required for Converting Nascent to Mature Lipid Droplets." ELife. ELife Sciences Publications, 26 Aug. 2016. Web.<https://elifesciences.org/content/5/e16582>. Pub Med ID: 27564575

* equal contribution